Tobacco use among adults--United States, 2005
Related Experiment Video
Updated: Jul 19, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Abstract:
Four of the Healthy People 2010 objectives regarding tobacco use are to reduce the prevalence of cigarette smoking to 12.0%, cigar smoking to 1.2%, use of smokeless tobacco to 0.4%, and to increase cessation attempts among adult smokers to 75.0%. To assess progress toward achieving these four objectives, CDC analyzed self-reported data from the 2005 National Health Interview Survey (NHIS). This report summarizes the results of these analyses, which indicated lagging progress on all four objectives. In 2005, approximately 20.9% of U.S. adults were current cigarette smokers, the same percentage as in 2004, suggesting that the 8-year decline in smoking prevalence among adults in the United States might be stalling. In addition, the findings indicated that, in 2005, an estimated 2.2% of U.S. adults were current cigar smokers, 2.3% used smokeless tobacco, and 42.5% of current cigarette smokers had stopped smoking for at least 1 day in the preceding 12 months because they were trying to quit. To meet the Healthy People objectives for 2010, full implementation of effective, comprehensive tobacco-control programs that address both initiation and cessation of tobacco use is needed in all states and U.S. territories.
Related Concept Videos
Statistical Methods for Analyzing Epidemiological Data
Stress Prevention and Stress Management Techniques IV
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Other Pulmonary Disorders
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...

